Significant Agreements - Additional Information (Details)						1 Months Ended				12 Months Ended
	Aug. 01, 2023 USD ($)	Dec. 16, 2021 OfficeSuite	Jun. 18, 2021 shares	Jun. 07, 2021 USD ($)	Jan. 27, 2021	Apr. 30, 2021 USD ($)	Jan. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Apr. 30, 2020	Aug. 04, 2024	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	May 07, 2021 shares
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common stock, shares, issued | shares											58,008,396	58,221,760
Research and development											$ 32,137,000	$ 72,787,000
General and administrative											40,973,000	32,852,000
Commitments And Contingencies (Note 7)
Percentage of equity interest on outstanding shares										20.00%
Amount of equity interest on outstanding shares											0
Future minimum lease payments											382,000
Lessee, Operating Lease, Existence of Option to Extend [true false]					true				true
Operating lease right-of-use assets											321,000	$ 5,580,000
Operating Lease, Liability											$ 362,000
Common Stock
Research And Development Arrangement Contract To Perform For Others [Line Items]
Shares repurchased | shares											152,694
Share-based compensation arrangement exercised | shares											101,900	67,196
Stanford Exclusive License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront license fees received								$ 50,000
Common stock, shares, issued | shares								600,000						600,000	640,861
Common stock additional paid in capital								$ 2,800,000						$ 2,800,000
Purchase of shares in private financings percentage								10.00%
Shares repurchased | shares			624,845
Research and development														2,800,000
General and administrative														200,000
Annual maintenance fees											$ 0
Patent fees											0
First commercial sale														50,000
Subsequent year commercial sale														200,000
Maximum future development and regulatory milestone payments											5,300,000
Sale-based milestone payments											7,500,000
Milestone payments											0
Stanford Exclusive License Agreement | First Year
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual maintenance fees														5,000
Stanford Exclusive License Agreement | Third Year
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual maintenance fees														10,000
Stanford Exclusive License Agreement | Sixth Year
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual maintenance fees														$ 25,000
License Agreement with Stanford | Common Stock
Research And Development Arrangement Contract To Perform For Others [Line Items]
Shares repurchased | shares			624,845
First Option Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common stock, shares, issued | shares							132,137
License execution fee							$ 10,000
Share-based compensation arrangement exercised | shares													0
Second Option Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Share-based compensation arrangement exercised | shares													0
Options fee						$ 30,000
Maintenance fees											0
LCGM Service Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development											1,700,000	$ 6,100,000
IDT License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development											0
Milestone payments											0
Exercise Fee				$ 500,000
Upfront payment				3,000,000
Milestones probable											0
IDT License Agreement | Research and Development Expenses
Research And Development Arrangement Contract To Perform For Others [Line Items]
Total consideration													$ 3,000,000
IDT License Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment				5,300,000
IDT License Agreement | Beta Thalassemia and Lysosomal Storage Disorders Fields
Research And Development Arrangement Contract To Perform For Others [Line Items]
Exercise Fee				1,000,000
Upfront payment				$ 8,800,000
Bayside Lease
Research And Development Arrangement Contract To Perform For Others [Line Items]
Tenant improvement allowance											14,900,000
Office and Laboratory Space | OfficeSuite		85,165
Lessee, Operating Lease, Existence of Option to Extend [true false]		true
Operating Lease, Liability											32,000,000
Asset purchase agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments	$ 1,000,000
Total consideration	500,000
Reimbursement of Research and Development amount due from realted party	$ 600,000
Loss on disposal of asset											100,000
Commitments And Contingencies (Note 7)											$ 0